Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
cancer
12
×
life sciences
12
×
national blog main
boston blog main
boston top stories
san francisco blog main
biotech
national top stories
new york blog main
san francisco top stories
clinical trials
national
new york top stories
san diego blog main
san diego top stories
texas blog main
texas top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
indiana blog main
indiana top stories
raleigh-durham blog main
raleigh-durham top stories
seattle blog main
seattle top stories
wisconsin blog main
wisconsin top stories
fda
startups
novartis
bristol-myers squibb
cancer immunotherapy
crispr
deals
eli lilly
investing
ipo
medical devices
What
new
12
×
drug
bio
cancer
ipo
medicines
roundup
companies
life
brings
cells
drugs
fda
genetic
lead
medicine
million
plan
san
science
sciences
targets
therapeutics
today
action
activity
advance
advantages
aim
antonio
approval
approvals
approved
bails
bar
based
begin
biogen
biogen’s
biologic
Language
unset
Current search:
new
×
cancer
×
" life sciences "
×
@xconomy.com
3 years ago
Codiak Bio’s IPO Brings In $82M as Exosome Clinical Trials Begin
@xconomy.com
4 years ago
Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More
@xconomy.com
4 years ago
Black Diamond Lines Up IPO as Lead Cancer Drug Nears Clinic
@xconomy.com
4 years ago
Bio Roundup: Ichnos Emerges, Beyond CAR-T, BridgeBio Bails & More
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
San Antonio Develops “Action Plan” to Draw Life Sciences Businesses
@xconomy.com
5 years ago
Genetic Medicine: FDA OKs 2nd Cancer Drug that Targets DNA, not Tissues
@xconomy.com
5 years ago
With OneOncology, Flatiron and Cancer Docs Aim to Boost Community Care
@xconomy.com
5 years ago
IPO Wave Rolls On as Five Life Science Firms Haul in $651M
@xconomy.com
5 years ago
CRISPR Risks? Researchers Stoke Fears of Cancer in Gene-Edited Cells
@xconomy.com
6 years ago
Synthorx Raises $63M to Advance Suite of Enhanced Cytokine Drugs